SUVEN — Suven Life Sciences Income Statement
0.000.00%
Last trade - 00:00- IN₹29.07bn
- IN₹27.41bn
- IN₹116.93m
Annual income statement for Suven Life Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | C2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 144 | 135 | 118 | 135 | 117 |
| Cost of Revenue | |||||
| Gross Profit | 128 | 134 | 117 | 132 | 107 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,341 | 975 | 1,345 | 1,395 | 1,387 |
| Operating Profit | -1,197 | -840 | -1,226 | -1,260 | -1,270 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,064 | -775 | -1,220 | -1,183 | -1,061 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -942 | -722 | -1,220 | -1,183 | -1,051 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -942 | -722 | -1,220 | -1,183 | -1,051 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -942 | -722 | -1,220 | -1,183 | -1,051 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.82 | -5.22 | -9.32 | -6.97 | -5.04 |